争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2026
诺华因溶出度不合格召回Diovan缬沙坦批次
宣布召回
诺华因其Diovan（缬沙坦）降压药特定批次未达到溶出度标准而召回该批次，可能影响药效。FDA将该通知定为II类召回，警告可能出现暂时或医学上可逆的不良健康后果。受影响批次包装标注AV5913C，为90片装160毫克片剂，有效期至2027年6月，由位于北卡罗来纳州格林维尔的Pantheon Manufacturing Services生产，并在美国全国分销。
品牌回应
召回 — Novartis
Novartis made the recall on August 4.
来源摘录
The batch that is being recalled has AV5913C on the packaging and include packages of 90 160-mg tablets with an expiration date of June 2027.
The valsartan drug was made by Novartis under the brand name Diovan and has been recalled as it does not meet dissolution specifications.
The US Food and Drug Administration has determined the notice as a Class II recall, which means exposure to the drug may lead to “temporary or medically reversible adverse health consequences.”